Cargando…

Impact of follow-up interval on patients with hepatocellular carcinoma after curative ablation

BACKGROUND: The optimal follow-up strategy after curative thermal ablation of hepatocellular carcinoma (HCC) remains unclear. METHODS: We retrospectively analyzed a prospective series of 616 patients who underwent curative thermal ablation for HCC within the Milan criteria. Multivariate Cox model wa...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Wenwu, Zheng, Yun, Zou, Ruhai, Shen, Jingxian, He, Wei, Yang, Zhiwen, Zhang, Yuanping, Li, Binkui, Yuan, Yunfei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267022/
https://www.ncbi.nlm.nih.gov/pubmed/30497418
http://dx.doi.org/10.1186/s12885-018-5069-z
_version_ 1783375971153346560
author Liu, Wenwu
Zheng, Yun
Zou, Ruhai
Shen, Jingxian
He, Wei
Yang, Zhiwen
Zhang, Yuanping
Li, Binkui
Yuan, Yunfei
author_facet Liu, Wenwu
Zheng, Yun
Zou, Ruhai
Shen, Jingxian
He, Wei
Yang, Zhiwen
Zhang, Yuanping
Li, Binkui
Yuan, Yunfei
author_sort Liu, Wenwu
collection PubMed
description BACKGROUND: The optimal follow-up strategy after curative thermal ablation of hepatocellular carcinoma (HCC) remains unclear. METHODS: We retrospectively analyzed a prospective series of 616 patients who underwent curative thermal ablation for HCC within the Milan criteria. Multivariate Cox model was used to identify independent predictive factors for recurrence; accordingly, patients were stratified into 2 groups with different relapse risks: a low-risk group (solitary tumor ≤3 cm) and a high-risk group (multiple tumors ≤3 cm or solitary tumor between 3 and 5 cm). Then, patients were classified into short- (< 4 months) or long-interval (4–6 months) surveillance groups according to follow-up intensity within the first 2 years after ablation. The overall survival (OS) of patients were compared between short- and long-interval groups in low- or high-risk groups, as well as the stage of recurrent tumors and the proportion of patients who received curative-intent retreatments. RESULTS: In the low-risk group, 54 (83.0%) and 18 (72.0%) of patients exhibited early relapse at the Barcelona Clinic Liver Cancer (BCLC) 0/A stage in the short- and long-interval groups, respectively (P = 0.172); accordingly, 44 (77.2%) and 18 (81.8%) of patients received curative-intent retreatment (P = 0.086) after recurrence. Hence, 5-year OS was similar between short- and long-interval groups (80.4% vs. 77.5%, P = 0.400) in low-risk patients. However, in the high-risk group, patients with a short interval exhibited early relapse more frequently at the BCLC 0/A stage (83% vs. 72%, P = 0.028), with a trend showing that the corresponding proportion of patients who received curative-intent retreatment greater than that in the long-interval group (64.2% vs. 37.5%, P = 0.087). Moreover, the short-interval group showed better 5-year OS than the long-interval group in high-risk patients (69.9% vs. 42.7%, P = 0.020). CONCLUSIONS: Compared to a short surveillance interval, a long surveillance interval does not reduce OS in low-risk patients; however, a long surveillance interval compromises OS in high-risk patients.
format Online
Article
Text
id pubmed-6267022
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-62670222018-12-05 Impact of follow-up interval on patients with hepatocellular carcinoma after curative ablation Liu, Wenwu Zheng, Yun Zou, Ruhai Shen, Jingxian He, Wei Yang, Zhiwen Zhang, Yuanping Li, Binkui Yuan, Yunfei BMC Cancer Research Article BACKGROUND: The optimal follow-up strategy after curative thermal ablation of hepatocellular carcinoma (HCC) remains unclear. METHODS: We retrospectively analyzed a prospective series of 616 patients who underwent curative thermal ablation for HCC within the Milan criteria. Multivariate Cox model was used to identify independent predictive factors for recurrence; accordingly, patients were stratified into 2 groups with different relapse risks: a low-risk group (solitary tumor ≤3 cm) and a high-risk group (multiple tumors ≤3 cm or solitary tumor between 3 and 5 cm). Then, patients were classified into short- (< 4 months) or long-interval (4–6 months) surveillance groups according to follow-up intensity within the first 2 years after ablation. The overall survival (OS) of patients were compared between short- and long-interval groups in low- or high-risk groups, as well as the stage of recurrent tumors and the proportion of patients who received curative-intent retreatments. RESULTS: In the low-risk group, 54 (83.0%) and 18 (72.0%) of patients exhibited early relapse at the Barcelona Clinic Liver Cancer (BCLC) 0/A stage in the short- and long-interval groups, respectively (P = 0.172); accordingly, 44 (77.2%) and 18 (81.8%) of patients received curative-intent retreatment (P = 0.086) after recurrence. Hence, 5-year OS was similar between short- and long-interval groups (80.4% vs. 77.5%, P = 0.400) in low-risk patients. However, in the high-risk group, patients with a short interval exhibited early relapse more frequently at the BCLC 0/A stage (83% vs. 72%, P = 0.028), with a trend showing that the corresponding proportion of patients who received curative-intent retreatment greater than that in the long-interval group (64.2% vs. 37.5%, P = 0.087). Moreover, the short-interval group showed better 5-year OS than the long-interval group in high-risk patients (69.9% vs. 42.7%, P = 0.020). CONCLUSIONS: Compared to a short surveillance interval, a long surveillance interval does not reduce OS in low-risk patients; however, a long surveillance interval compromises OS in high-risk patients. BioMed Central 2018-11-29 /pmc/articles/PMC6267022/ /pubmed/30497418 http://dx.doi.org/10.1186/s12885-018-5069-z Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Liu, Wenwu
Zheng, Yun
Zou, Ruhai
Shen, Jingxian
He, Wei
Yang, Zhiwen
Zhang, Yuanping
Li, Binkui
Yuan, Yunfei
Impact of follow-up interval on patients with hepatocellular carcinoma after curative ablation
title Impact of follow-up interval on patients with hepatocellular carcinoma after curative ablation
title_full Impact of follow-up interval on patients with hepatocellular carcinoma after curative ablation
title_fullStr Impact of follow-up interval on patients with hepatocellular carcinoma after curative ablation
title_full_unstemmed Impact of follow-up interval on patients with hepatocellular carcinoma after curative ablation
title_short Impact of follow-up interval on patients with hepatocellular carcinoma after curative ablation
title_sort impact of follow-up interval on patients with hepatocellular carcinoma after curative ablation
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267022/
https://www.ncbi.nlm.nih.gov/pubmed/30497418
http://dx.doi.org/10.1186/s12885-018-5069-z
work_keys_str_mv AT liuwenwu impactoffollowupintervalonpatientswithhepatocellularcarcinomaaftercurativeablation
AT zhengyun impactoffollowupintervalonpatientswithhepatocellularcarcinomaaftercurativeablation
AT zouruhai impactoffollowupintervalonpatientswithhepatocellularcarcinomaaftercurativeablation
AT shenjingxian impactoffollowupintervalonpatientswithhepatocellularcarcinomaaftercurativeablation
AT hewei impactoffollowupintervalonpatientswithhepatocellularcarcinomaaftercurativeablation
AT yangzhiwen impactoffollowupintervalonpatientswithhepatocellularcarcinomaaftercurativeablation
AT zhangyuanping impactoffollowupintervalonpatientswithhepatocellularcarcinomaaftercurativeablation
AT libinkui impactoffollowupintervalonpatientswithhepatocellularcarcinomaaftercurativeablation
AT yuanyunfei impactoffollowupintervalonpatientswithhepatocellularcarcinomaaftercurativeablation